Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial

6533b837fe1ef96bd12a1fdf

RESEARCH PRODUCT

Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial

Prandoni P Noventa F Quintavalla R Bova C Siragusa S Bucherini E Astorri F Cuppini S Dalla Valle F Lensing Aw Prins Mh Villalta S Canano Investigators Collaborators […Vedovetto V Barbar S Campello E Milan M Filippi L Rocci A Chiappetta P Pellegrini R Fiaschi E Vallone G D'amico E Noto A Pili C Costantini E Gasperon M Palareti G Malato A Saccullo G Brini C Bitti G Marzolo M Ramazzina E Zamboni S.Benilde Cosmi

subject

Adult Male musculoskeletal diseases medicine.medical_specialty Time Factors Immunology Thigh behavioral disciplines and activities Biochemistry Postthrombotic Syndrome Settore MED/15 - Malattie Del Sangue law.invention POST-THROMBOTIC SYNDROME Young Adult Randomized controlled trial law medicine Humans Knee Aged Aged 80 and over Venous Thrombosis First episode VENOUS THROMBOEMBOLISM business.industry Pruritus Hazard ratio Cell Biology Hematology Middle Aged musculoskeletal system medicine.disease Thrombosis humanities Confidence interval Discontinuation Surgery Venous thrombosis Treatment Outcome medicine.anatomical_structure Thigh Erythema Patient Compliance Female venous thrombosis business Stockings Compression Follow-Up Studies

description

Abstract Although below-knee compression elastic stockings (CES) are effective for the prevention of the postthrombotic syndrome (PTS), a substantial number of patients with deep venous thrombosis still develop PTS. In the present open-label, randomized clinical trial, we compared thigh-length with below-knee CES for the prevention of PTS. A total of 267 patients with the first episode of proximal deep venous thrombosis were randomized to wear either thigh-length or below-knee CES for 2 years. After 3, 6, 12, 18, 24, and 36 months, they were assessed for PTS manifestations according to the Villalta scale. PTS developed in 44 (32.6%) of the 135 patients randomized to thigh-length CES and in 47 (35.6%) of the 132 allocated to below-knee CES, for an adjusted hazard ratio of 0.93 (95% confidence interval, 0.62-1.41). Severe PTS developed in 3 patients in each group. CES-related side effects developed in 55 (40.7%) of the 135 patients allocated to thigh-length CES and in 36 (27.3%) of those randomized to the below-knee group (P = .017), and led to premature discontinuation of their use in 29 (21.5%) and 18 (13.6%) patients, respectively. We conclude that thigh-length CES do not offer a better protection against PTS than below-knee CES and are less well tolerated. This study is registered as Clinical Trial number NCT00426075.

year	journal	country	edition	language
2012-02-09	Blood

https://doi.org/10.1182/blood-2011-11-391961